2023年3月27日,

SeqOne基因組關閉€20 m係列加速部署其基因組醫學平台公司的資金將推動國際部署下一代基因組分析平台,使個性化醫學癌症以及罕見的遺傳性疾病。蒙彼利埃,2022年1月24日- SeqOne基因組學、個性化醫療提供者的基因組分析解決方案今天宣布一係列融資輪€20米。圓,由諸聖Merieux Equity Partners,加上軟件俱樂部和現有投資者,Elaia和IRDI資本Investissement,將使SeqOne基因組加快其國際銷售和開發新的協作基因組分析工具來促進不同學科之間的通信在醫學團隊,為了改善病人結果癌症和遺傳性疾病。公司將加大投資的發展genomic-aware數據改善湖大數據的使用和機器學習方法在基因組分析,目的是更好的解決分子生物學的飛速發展需要實驗室提供基因組分析在臨床常規環境,以及生物製藥公司開發新療法。SeqOne的基於雲的解決方案管理整個基因組分析過程從原始數據到最終報告提交給臨床醫生。解決方案的端到端方法提供更好的分析性能,高水平的可跟蹤性和提高運作效率和已經采取的醫院和中心實驗室、生物製藥以及產卵的夥伴關係與主要生產商的基因組分析硬件和試劑。尼古拉斯•菲利普博士SeqOne基因組的聯合創始人和首席執行官說:“我們非常高興有封閉的這一輪與主要投資者帶來在科技密集型的豐富經驗,醫療和生物療法和他們分享我們的願景建設SeqOne成為全球領先的個性化醫療。資金將給我們的資源,我們需要加強我們的解決方案並進行商業化進行基因組分析更容易獲得和負擔,這樣每個病人可以受益於個性化醫學recommandations。”“基因組學分析市場正在經曆指數增長的個性化醫療的需要。快速擴張的可用genomic-linked治療,治療的相互作用的複雜性,和驚人的體積的生物和醫學數據分解成每個醫療決定,生物學家和醫生必須能夠訪問實時可靠、可行的分析”,聲明法比Collangettes諸聖主管。“我們特別SeqOne印象深刻的創新的技術方法,使改進的基因測試精度,同時減少周轉時間和成本,從而提供一個關鍵的競爭優勢在這個快速增長的市場。” With the closing of this round, SeqOne’s board of directors will be: Sacha Loiseau, Ph.D. independent board member and Chairman of the Board, Fabien Collangettes, Director at Omnes, Yoann Bonnamour, Investment Manager at Merieux Equity Partners, Marc Rougier, Partner at Elaia, Nicolas Philippe, co-founder and CEO of SeqOne Genomics and Jean-Marc Holder, Cofounder and Chief Strategy and Innovation officer of SeqOne Genomics. This new funding round brings the total amount raised by SeqOne Genomics since its founding in 2017 to €23M. The company currently employs over 40 staff, primarily experts in genomic medicine, data science, bioinformatics, software development and regulatory compliance / quality assurance. It plans to double its staff within the year to execute its ambitious plans. Advisors: Market intelligence : Clara Niarfeix – Alcimed Intellectual property: Claire Verschelde, PhD – ICOSA Financial due diligence : Crowe HAF Maxime Hazim and Julien Latrubesse About SeqOne Genomics SeqOne Genomics offers high performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary GeniOS™ genomics operating system to dramatically reduce turnaround times and costs while delivering a comprehensive and actionable insights for personalised medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize.Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club.